UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis

Digestive diseases and sciences, 2021-01, Vol.66 (1), p.199-205

2021

Volltextzugriff (PDF)

Advances in cholangiocyte immunobiology

American journal of physiology: Gastrointestinal and liver physiology, 2012-11, Vol.303 (10), p.G1077-G1086

2012

Volltextzugriff (PDF)

Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort

Inflammatory bowel diseases, 2019-03, Vol.25 (4), p.767-774

2019

Volltextzugriff (PDF)

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort

Inflammatory bowel diseases, 2019-09, Vol.25 (9), p.1569-1576

2019

Volltextzugriff (PDF)

Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study

The American journal of gastroenterology, 2022-10, Vol.117 (10), p.1639-1647

2022

Volltextzugriff (PDF)

S3309 Patients’ Perspectives, Experiences, and Concerns With Crohn’s Perianal Fistulae: Qualitative Insights From Crohn’s Disease Social Media Platforms

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S1364-S1364

2021

Volltextzugriff (PDF)

Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial

The American journal of gastroenterology, 2022-09, Vol.117 (9), p.1508-1518

2022

Volltextzugriff (PDF)

S878 Patient Reported Outcomes (PRO2) Are a Sensitive Measure of Endoscopic Disease Activity in Ulcerative Colitis

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S412-S412

2021

Volltextzugriff (PDF)

S741 Psychological Distress During a Global Pandemic: Prevalence and Risk Factors in a National Cohort of Inflammatory Bowel Disease (IBD) Patients

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S340-S341

2021

Volltextzugriff (PDF)

S742 A National Cohort of IBD Patients Exhibit Strong COVID-19 Safety Practice Beliefs

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S341-S341

2021

Volltextzugriff (PDF)

S950 Symptomology Following SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease Relative to Healthcare Workers

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S453-S455

2021

Volltextzugriff (PDF)

S926 Effects of Immune Modifying Therapies on Antibody Responses Following SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S438-S439

2021

Volltextzugriff (PDF)

S904 Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease After SARS-CoV-2 mRNA Vaccination

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S427-S428

2021

Volltextzugriff (PDF)

An innovative technique for management of esophageal pill impaction

Gastrointestinal endoscopy, 2015-08, Vol.82 (2), p.422-423

2015

Volltextzugriff (PDF)

Su1836 COST-EFFECTIVENESS OF DE SIMONE MULTI-STRAIN PROBIOTIC IN PRIMARY AND SECONDARY PROPHYLAXIS OF POUCHITIS IN PATIENTS WITH ULCERATIVE COLITIS AFTER ILEAL POUCH ANAL ANASTOMOSIS

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-835-S-836

2024

Volltextzugriff (PDF)

Tu1848 - Fecal Microbiota Transplantation is Effective in Treatment of Recurrent Clostridium Diffcile Infection in Patients with Inflammtory Bowel Disaese: Systematic Review and Meta-Analysis

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1037-S-1037

2018

Volltextzugriff (PDF)

Su1508: PRIOR EXPOSURE TO OTHER ADVANCED THERAPIES DOES NOT INCREASE THE RISK OF TNF INHIBITOR THERAPY FAILURE IN INFLAMMATORY BOWEL DISEASE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-606-S-606

2022

Volltextzugriff (PDF)

Mo1865 WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS WITH PARTIAL OR NON-RESPONSE TO INFLIXIMAB AND ALLOWS FOR EARLY OPTIMIZATION OF THERAPY IN INFLAMMATORY BOWEL DISEASE

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-954-S-955

2020

Volltextzugriff (PDF)

P120 PRE-POUCH ILEITIS IS A RISK FACTOR FOR DEVELOPMENT OF CROHN'S DISEASE-LIKE COMPLICATIONS, NEED FOR BIOLOGIC THERAPY AND POUCH FAILURE

Gastroenterology (New York, N.Y. 1943), 2020-02, Vol.158 (3), p.S72-S73

2020

Volltextzugriff (PDF)

Mo1497: PROPHYLACTIC POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY MAY REDUCE THE RISK OF POUCH FAILURE IN PATIENTS UNDERGOING INTENTIONAL ILEAL POUCH-ANAL ANASTOMOSIS FOR CROHN’S DISEASE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-790-S-790

2022

Volltextzugriff (PDF)

656 Ustekinumab Dose Escalation Is Effective in Treatment of Crohn's Disease

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S384-S385

2019

Volltextzugriff (PDF)

735 Crohn's Disease Patients Who Do Not Qualify for Clinical Trials Have Similar Clinical and Endoscopic Response Rates to Ustekinumab to Those Who Qualify for Clinical Trials

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S432-S433

2019

Volltextzugriff (PDF)

P120 PRE-POUCH ILEITIS IS A RISK FACTOR FOR DEVELOPMENT OF CROHN’S DISEASE-LIKE COMPLICATIONS, NEED FOR BIOLOGIC THERAPY AND POUCH FAILURE

Inflammatory bowel diseases, 2020-01, Vol.26 (Supplement_1), p.S44-S44

2020

Volltextzugriff (PDF)

P054 WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE

Gastroenterology (New York, N.Y. 1943), 2019-02, Vol.156 (3), p.S38-S38

2019

Volltextzugriff (PDF)

857 SIMILAR 6-MONTH OUTCOMES AMONG INFLAMMATORY BOWEL DISEASE PATIENTS INITIATING INFLIXIMAB WITH WEEK 10 PROACTIVE THERAPEUTIC DRUG MONITORING COMPARED TO CONVENTIONAL MANAGEMENT

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-174-S-174

2021

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Englisch
(142)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis

Advances in cholangiocyte immunobiology

Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort

Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study

S3309 Patients’ Perspectives, Experiences, and Concerns With Crohn’s Perianal Fistulae: Qualitative Insights From Crohn’s Disease Social Media Platforms

Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial

S878 Patient Reported Outcomes (PRO2) Are a Sensitive Measure of Endoscopic Disease Activity in Ulcerative Colitis

S741 Psychological Distress During a Global Pandemic: Prevalence and Risk Factors in a National Cohort of Inflammatory Bowel Disease (IBD) Patients

S742 A National Cohort of IBD Patients Exhibit Strong COVID-19 Safety Practice Beliefs

S950 Symptomology Following SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease Relative to Healthcare Workers

S926 Effects of Immune Modifying Therapies on Antibody Responses Following SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease

S904 Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease After SARS-CoV-2 mRNA Vaccination

An innovative technique for management of esophageal pill impaction

Su1836 COST-EFFECTIVENESS OF DE SIMONE MULTI-STRAIN PROBIOTIC IN PRIMARY AND SECONDARY PROPHYLAXIS OF POUCHITIS IN PATIENTS WITH ULCERATIVE COLITIS AFTER ILEAL POUCH ANAL ANASTOMOSIS

Tu1848 - Fecal Microbiota Transplantation is Effective in Treatment of Recurrent Clostridium Diffcile Infection in Patients with Inflammtory Bowel Disaese: Systematic Review and Meta-Analysis

Su1508: PRIOR EXPOSURE TO OTHER ADVANCED THERAPIES DOES NOT INCREASE THE RISK OF TNF INHIBITOR THERAPY FAILURE IN INFLAMMATORY BOWEL DISEASE

Mo1865 WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS WITH PARTIAL OR NON-RESPONSE TO INFLIXIMAB AND ALLOWS FOR EARLY OPTIMIZATION OF THERAPY IN INFLAMMATORY BOWEL DISEASE

P120 PRE-POUCH ILEITIS IS A RISK FACTOR FOR DEVELOPMENT OF CROHN'S DISEASE-LIKE COMPLICATIONS, NEED FOR BIOLOGIC THERAPY AND POUCH FAILURE

Mo1497: PROPHYLACTIC POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY MAY REDUCE THE RISK OF POUCH FAILURE IN PATIENTS UNDERGOING INTENTIONAL ILEAL POUCH-ANAL ANASTOMOSIS FOR CROHN’S DISEASE

656 Ustekinumab Dose Escalation Is Effective in Treatment of Crohn's Disease

735 Crohn's Disease Patients Who Do Not Qualify for Clinical Trials Have Similar Clinical and Endoscopic Response Rates to Ustekinumab to Those Who Qualify for Clinical Trials

P120 PRE-POUCH ILEITIS IS A RISK FACTOR FOR DEVELOPMENT OF CROHN’S DISEASE-LIKE COMPLICATIONS, NEED FOR BIOLOGIC THERAPY AND POUCH FAILURE

P054 WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE

857 SIMILAR 6-MONTH OUTCOMES AMONG INFLAMMATORY BOWEL DISEASE PATIENTS INITIATING INFLIXIMAB WITH WEEK 10 PROACTIVE THERAPEUTIC DRUG MONITORING COMPARED TO CONVENTIONAL MANAGEMENT

Suchergebnisse filtern